Moody’s rates Pfizer notes A1

Moody's Investors Service said it assigned an A1 rating to the new senior unsecured note issuance of Pfizer Inc.

There were no changes to Pfizer's existing ratings including the A1 senior unsecured rating and the Prime-1 commercial paper rating, the agency said.

The outlook is stable.

Proceeds of the offering are for general corporate purposes including the repayment of existing debt obligations.

“Pfizer's A1 rating reflects its position as one of the world's largest pharmaceutical companies, strong diversity, high profitability and strong cash flow,” Moody’s said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.